Peer-reviewedCC BY-NC 4.0Bioorganic and Medicinal Chemistry Letters
Identification of a novel NR2B-selective NMDA receptor antagonist using a virtual screening approach
Abstract
We report the identification of a novel NR2B-selective NMDAR antagonist with an original scaffold, LSP10-0500. This compound was identified by a virtual high-throughput screening approach on the basis of a quantitative pharmacophore model of NR2B-specific NMDAR antagonists. A SAR study around LSP10-0500 is also described.
Related
- Discovery of Selective Small-Molecule Ligands of SV2C by AI-Enhanced Virtual Screening and Experimental Validation
- Structural Basis of NR2B-Selective Antagonist Recognition by N-Methyl-d-aspartate Receptors
- Pharmacological Activity of Motugivatrep, a Novel Antagonist of Transient Receptor Potential Cation Channel Subfamily V Member 1
- The sphingosine-1-phosphate receptor functional antagonist fingolimod exacerbates neuroinflammation and tau pathology in a mouse model of tauopathy
- Screening of endophytic bacteria of Leucojum aestivum ‘Gravety giant’ as a potential source of alkaloids and as antagonist to some plant fungal pathogens
BibTeX
@article{mony2026identification,
title = {{Identification of a novel NR2B-selective NMDA receptor antagonist using a virtual screening approach}},
author = {Laetitia Mony and Nicolas Triballeau and Pierre Paoletti and Francine Acher and Hugues-Olivier Bertrand},
journal = {Bioorganic and Medicinal Chemistry Letters},
year = {2026},
month = oct,
doi = {10.1016/j.bmcl.2010.07.043},
url = {https://hal.science/hal-05773222v1},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Identification of a novel NR2B-selective NMDA receptor antagonist using a virtual screening approach
AU - Laetitia Mony
AU - Nicolas Triballeau
AU - Pierre Paoletti
AU - Francine Acher
AU - Hugues-Olivier Bertrand
PY - 2026
DA - 2026/10/01
JO - Bioorganic and Medicinal Chemistry Letters
DO - 10.1016/j.bmcl.2010.07.043
UR - https://hal.science/hal-05773222v1
AB - We report the identification of a novel NR2B-selective NMDAR antagonist with an original scaffold, LSP10-0500. This compound was identified by a virtual high-throughput screening approach on the basis of a quantitative pharmacophore model of NR2B-specific NMDAR antagonists. A SAR study around LSP10-0500 is also described.
SN - 0960-894X
ER -